LGND · Company research
Ligand Pharmaceuticals Inc. (LGND): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance | Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts - Yahoo Finance UK | Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 13, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada | Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance | Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits | TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari Stocktwits | View source ↗ | Stocktwits | Oct 4, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance | Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal Yahoo Finance | View source ↗ | Yahoo Finance | Sep 29, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution - ChartMill | Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution ChartMill | View source ↗ | ChartMill | Sep 28, 2026 | neutral | 0 | 0.6 |
| Up to $47 million could help advance AvenCell's treatments for two blood cancers. - Stock Titan | Up to $47 million could help advance AvenCell's treatments for two blood cancers. Stock Titan | View source ↗ | Stock Titan | Sep 24, 2026 | neutral | 0 | 0.6 |
| A production platform used in six approved biologics gets new funding. Primrose Bio will help expand its reach. - Stock Titan | A production platform used in six approved biologics gets new funding. Primrose Bio will help expand its reach. Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| About 1 in 3 European children and teens may be nearsighted by 2050. Ligand buys rights to a children's eye drop. - Stock Titan | About 1 in 3 European children and teens may be nearsighted by 2050. Ligand buys rights to a children's eye drop. Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock - Investor's Business Daily | Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock Investor's Business Daily | View source ↗ | Investor's Business Daily | Aug 14, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance | Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run Yahoo Finance | View source ↗ | Yahoo Finance | Aug 14, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow While Earnings Look Overvalued - Simply Wall Street | Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow While Earnings Look Overvalued Simply Wall Street | View source ↗ | Simply Wall Street | Aug 12, 2026 | neutral | 0 | 0.6 |
| This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026 - Investor's Business Daily | This Stock Of The Day Rides Big Pharma Royalties; It's Up 56% In 2026 Investor's Business Daily | View source ↗ | Investor's Business Daily | Jul 27, 2026 | neutral | 0 | 0.6 |
| Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings - Yahoo Finance | Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Jul 16, 2026 | neutral | 0 | 0.6 |
| Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator - Seeking Alpha | Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator Seeking Alpha | View source ↗ | Seeking Alpha | Jun 30, 2026 | neutral | 0 | 0.6 |
| LGND Stock Rips Higher As Royalty Story Deepens - StocksToTrade | LGND Stock Rips Higher As Royalty Story Deepens StocksToTrade | View source ↗ | StocksToTrade | Jun 23, 2026 | neutral | 0 | 0.6 |
| LGND Stock Draws Traders As Royalties Rise, Debt Deal Hits - StocksToTrade | LGND Stock Draws Traders As Royalties Rise, Debt Deal Hits StocksToTrade | View source ↗ | StocksToTrade | Jun 23, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.